Bokf Na Sells 1,085 Shares of Elevance Health, Inc. (NYSE:ELV)

BOKF NA trimmed its stake in Elevance Health, Inc. (NYSE:ELV - Free Report) by 10.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,586 shares of the company's stock after selling 1,085 shares during the quarter. BOKF NA's holdings in Elevance Health were worth $3,654,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Accredited Wealth Management LLC purchased a new stake in Elevance Health during the fourth quarter valued at about $25,000. Flagship Wealth Advisors LLC acquired a new position in Elevance Health in the 4th quarter worth approximately $26,000. OFI Invest Asset Management purchased a new position in Elevance Health during the 4th quarter worth approximately $29,000. WealthTrak Capital Management LLC acquired a new stake in Elevance Health during the 4th quarter valued at $29,000. Finally, Lee Danner & Bass Inc. purchased a new stake in shares of Elevance Health in the fourth quarter valued at $30,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Stock Performance

NYSE:ELV traded down $7.86 during midday trading on Friday, reaching $404.52. The stock had a trading volume of 948,113 shares, compared to its average volume of 1,472,531. The stock has a market capitalization of $91.40 billion, a P/E ratio of 15.80, a PEG ratio of 1.18 and a beta of 0.66. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. Elevance Health, Inc. has a 1-year low of $362.21 and a 1-year high of $567.26. The firm's fifty day simple moving average is $424.13 and its 200-day simple moving average is $404.51.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The company reported $11.97 earnings per share for the quarter, topping the consensus estimate of $10.60 by $1.37. The business had revenue of $48.77 billion during the quarter, compared to analysts' expectations of $46.26 billion. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. On average, equities research analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Investors of record on Tuesday, June 10th will be paid a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a yield of 1.69%. The ex-dividend date of this dividend is Tuesday, June 10th. Elevance Health's payout ratio is currently 26.69%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ELV shares. Guggenheim reiterated a "buy" rating and set a $518.00 price target on shares of Elevance Health in a report on Wednesday, April 23rd. StockNews.com raised Elevance Health from a "hold" rating to a "buy" rating in a research note on Thursday, March 20th. Robert W. Baird restated a "neutral" rating and set a $529.00 price target (down from $625.00) on shares of Elevance Health in a report on Tuesday, April 15th. Barclays upped their price objective on shares of Elevance Health from $512.00 to $522.00 and gave the company an "overweight" rating in a research note on Wednesday, April 23rd. Finally, Royal Bank of Canada restated an "outperform" rating and set a $478.00 price target on shares of Elevance Health in a report on Wednesday, April 23rd. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $510.38.

Insider Buying and Selling at Elevance Health

In other news, CFO Mark Kaye sold 4,588 shares of the firm's stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $424.82, for a total transaction of $1,949,074.16. Following the completion of the transaction, the chief financial officer now directly owns 18,977 shares of the company's stock, valued at approximately $8,061,809.14. This trade represents a 19.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of Elevance Health stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the sale, the executive vice president now owns 10,116 shares in the company, valued at approximately $4,008,970.80. This trade represents a 25.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,535 shares of company stock valued at $3,521,612 in the last ninety days. Company insiders own 0.29% of the company's stock.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.